sirolimus and Mandibular-Diseases

Antiresorptive agent-related osteonecrosis of the jaw results in appreciable morbidity in affected patients. Nowadays many physicians prescribe an antiangiogenic agent for the management of malignant metastases. Everolimus is a serine-threonine kinase that acts as an inhibitor of mammalian target of rapamycin, which results in reduced growth of cells, angiogenesis, and survival of cells. We report the first case to our knowledge of osteonecrosis of the jaw that seemed to result from the additive effect of everolimus.

Topics: Angiogenesis Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Everolimus; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Osteonecrosis; Sirolimus; Thyroid Neoplasms; Thyroidectomy; Zoledronic Acid